Riise Stensland Hilde Monica Frostad, Persichetti Emanuele, Sorriso Carmelita, Hansen Gaute Martin, Bibi Lucia, Paciotti Silvia, Balducci Chiara, Beccari Tommaso
Department of Medical Genetics, University Hospital of Northern Norway, Tromsø, Norway.
Department of Internal Medicine, University of Perugia, Perugia, Italy.
Mol Genet Metab. 2008 Aug;94(4):476-480. doi: 10.1016/j.ymgme.2008.04.010. Epub 2008 Jun 18.
Beta-mannosidosis (OMIM # 248510) is an autosomal-recessive lysosomal storage disorder caused by deficiency of the lysosomal enzyme beta-mannosidase (MANBA, E.C. 3.2.1.25). The disorder has been reported in goat, cattle and man. The human disorder is rare and only 20 cases in 16 families have been reported. We have sequenced the exons and exon-intron borders in a European patient with infantile onset of beta-mannosidosis. The patient was compound heterozygous for a silent mutation (c.375A>G) in exon 3 causing alternative splicing, and a missense mutation (c.1513T>C, p.Ser505Pro) in exon 12. The alternative splicing event deleted four nucleotides from the transcript and was predicted to result in premature termination of translation. In order to evaluate the consequence of the missense mutation, we inserted the human beta-mannosidase gene into an expression vector, performed site-directed mutagenesis and expressed the normal and mutant enzyme in COS-7 cells. We also included the previously reported beta-mannosidosis-associated missense mutations c.544C>T (p.Arg182Trp) and c.1175G>A (p.Gly392Glu), which were found in patients presenting a milder phenotype. Cells transfected with the wild-type construct showed a 33-fold increase in beta-mannosidase activity compared to mock-transfected cells, whereas cells transfected with the mutant constructs showed no detectable increase in activity. We propose that the milder phenotype described in some beta-mannosidosis patients with missense mutations in the MANBA gene is not due to residual beta-mannosidase activity, but rather caused by epigenetic and/or environmental factors.
β-甘露糖苷贮积症(OMIM # 248510)是一种常染色体隐性溶酶体贮积病,由溶酶体酶β-甘露糖苷酶(MANBA,E.C. 3.2.1.25)缺乏引起。该疾病已在山羊、牛和人类中报道。人类的这种疾病很罕见,仅报道了16个家族中的20例病例。我们对一名患有婴儿型β-甘露糖苷贮积症的欧洲患者的外显子及外显子-内含子边界进行了测序。该患者为复合杂合子,外显子3中有一个导致可变剪接的沉默突变(c.375A>G),外显子12中有一个错义突变(c.1513T>C,p.Ser505Pro)。可变剪接事件使转录本缺失了四个核苷酸,并预计会导致翻译提前终止。为了评估错义突变的后果,我们将人β-甘露糖苷酶基因插入表达载体,进行定点诱变,并在COS-7细胞中表达正常和突变酶。我们还纳入了先前报道的与β-甘露糖苷贮积症相关的错义突变c.544C>T(p.Arg182Trp)和c.1175G>A(p.Gly392Glu),这些突变见于表现出较轻表型的患者。与mock转染细胞相比,用野生型构建体转染的细胞β-甘露糖苷酶活性增加了33倍,而用突变构建体转染的细胞未检测到活性增加。我们提出,一些在MANBA基因中存在错义突变的β-甘露糖苷贮积症患者所表现出的较轻表型并非由于残留的β-甘露糖苷酶活性,而是由表观遗传和/或环境因素引起的。